Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial

作     者：Morteza Shakhsi Niaee Peyman Namdar Abbas Allami Leila Zolghadr Amir Javadi Amin Karampour Mehran Varnaseri Behzad Bijani Fatemeh Cheraghi Yazdan Naderi Fatemeh Amini Masoumeh Karamyan Mohammad Jafar YadYad Ramin Jamshidian Nematollah Gheibi Morteza Shakhsi Niaee;Peyman Namdar;Abbas Allami;Leila Zolghadr;Amir Javadi;Amin Karampour;Mehran Varnaseri;Behzad Bijani;Fatemeh Cheraghi;Yazdan Naderi;Fatemeh Amini;Masoumeh Karamyan;Mohammad Jafar Yad Yad;Ramin Jamshidian;Nematollah Gheibi

作者机构：Sciences and Technology ParkQazvinIran Department of SurgeryQazvin University of Medical SciencesQazvinIran Department of Infectious DiseasesClinical Research Development UnitBouAliSina HospitalQazvin University of Medical SciencesQazvinIran Department of ChemistryImam Khomeini International University QazvinIran Department of Social Sciences School of MedicineQazvin University of Medical SciencesQazvinIran Infectious and Tropical Diseases Research CenterAhvaz Jundishapur University of Medical SciencesAhvazIran Department of Infectious DiseasesQazvin University of Medical SciencesQazvinIran Cellular and Molecular Research CenterResearch Institute for Prevention of Non-Communicable DiseasesQazvin University of Medical SciencesQazvinIran Department of Persian MedicineSchool of MedicineShiraz University of Medical SciencesShirazIran 

出 版 物：《Asian Pacific Journal of Tropical Medicine》 (亚太热带医药杂志（英文版）)

年 卷 期：2021年第14卷第6期

页      面：266-273页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：Research and Technology of Qazvin University of Medical Sciences Cellular and Molecular Research Center and Infection Prevention Center of Qazvin University of Medical Sciences 

主　　题：SARS-COV-2 Ivermectin Randomized controlled trial Dose-respond relationship 

摘      要：Objective: To evaluate different doses of ivermectin in adult patients with mild COVID-19 and to evaluate the effect of ivermectin on mortality and clinical ***: A randomized, double-blind, placebo-controlled, multicenter clinical trial was performed at five hospitals. A total of 180 mild hospitalized patients with COVID-19 confirmed by PCR or chest image tests were enrolled and allocated to six arms including hydroxychloroquine 200 mg twice per day, placebo plus hydroxychloroquine 200 mg twice per day, single dose ivermectin(200 μg/kg), three low interval doses of ivermectin(200, 200, 200 μg/kg), single dose ivermectin(400 μg/kg), and three high interval doses of ivermectin(400, 200, 200 μg/kg). The primary endpoint of this trial was all-cause of mortality or clinical recovery. The radiographic findings, hospitalization and low O_2 saturation duration, and hematological variables of blood samples were analyzed. Results: A total of 16.7%(5/30) and 20.0%(6/30) patients died in arms treated with hydroxychloroquine 200 mg twice per day and placebo plus hydroxychloroquine 200 mg twice per day, respectively, and a reduction in mortality rate in patients receiving ivermectin treatment to 0%, 10%, 0% and 3.3% for arms 1-4 were observed. Risk of mortality was also decreased about 15% in the ivermectin treated arms. Conclusions: Ivermectin as an adjunct reduces the rate of mortality, time of low O_2 saturation, and duration of hospitalization in adult COVID-19 patients. The improvement of other clinical parametersshows that ivermectin, with a wide margin of safety, had a high therapeutic effect on COVID-19.